Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
- 12 November 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Human Genetics
- Vol. 27 (3), 422-431
- https://doi.org/10.1038/s41431-018-0301-5
Abstract
According to the current dogma, cholesteryl ester transfer protein (CETP) decreases high-density lipoprotein (HDL)-cholesterol (C) and increases low-density lipoprotein (LDL)-C. However, detailed insight into the effects of CETP on lipoprotein subclasses is lacking. Therefore, we used a Mendelian randomization approach based on a genetic score for serum CETP concentration (rs247616, rs12720922 and rs1968905) to estimate causal effects per unit (µg/mL) increase in CETP on 159 standardized metabolic biomarkers, primarily lipoprotein subclasses. Metabolic biomarkers were measured by nuclear magnetic resonance (NMR) in 5672 participants of the Netherlands Epidemiology of Obesity (NEO) study. Higher CETP concentrations were associated with less large HDL (largest effect XL-HDL-C, P = 6 × 10–22) and more small VLDL components (largest effect S-VLDL cholesteryl esters, P = 6 × 10–6). No causal effects were observed with LDL subclasses. All these effects were replicated in an independent cohort from European ancestry (MAGNETIC NMR GWAS; n ~20,000). Additionally, we assessed observational associations between ELISA-measured CETP concentration and metabolic measures. In contrast to results from Mendelian randomization, observationally, CETP concentration predominantly associated with more VLDL, IDL and LDL components. Our results show that CETP is an important causal determinant of HDL and VLDL concentration and composition, which may imply that the CETP inhibitor anacetrapib decreased cardiovascular disease risk through specific reduction of small VLDL rather than LDL. The contrast between genetic and observational associations might be explained by a high capacity of VLDL, IDL and LDL subclasses to carry CETP, thereby concealing causal effects on HDL.Funding Information
- ZonMw (91617027, 91614023)
- European Commission (Health-2013-INNOVATION-1-602757)
- Hartstichting (CVON2011-9)
This publication has 54 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- An integrated map of genetic variation from 1,092 human genomesNature, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Detailed metabolic and genetic characterization reveals new associations for 30 known lipid lociHuman Molecular Genetics, 2011
- Genetically Elevated Apolipoprotein A-I, High-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart DiseaseJournal of Clinical Endocrinology & Metabolism, 2010
- Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide AnalysisPLoS Genetics, 2009
- Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitorsEuropean Heart Journal, 2009
- Mendelian RandomizationJama-Journal Of The American Medical Association, 2009
- A new multipoint method for genome-wide association studies by imputation of genotypesNature Genetics, 2007
- Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasmaBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990